Chemoresistant glioma (GLTMZ) promotes M2-like polarization (CD11b+Gr1+CD68+CD206+) characterized by a significant increase in the release of immunosuppressive interleukin (IL)-10, which sustains tumor proliferation (26), CD206 expression, and arginase activity (proposed M2-like marker). The gene discussed is MRC1; the disease is central nervous system cancer.